Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 12383990)

1.

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR.

Lancet. 2002 Oct 5;360(9339):1071-3.

PMID:
12383990
2.

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.

3.
4.
5.

COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.

Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. Review. No abstract available.

PMID:
12616850
6.

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.

7.
8.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

9.

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.

Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA.

Lancet. 2004 May 29;363(9423):1751-6.

PMID:
15172772
10.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
12.

Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.

Moore PA, Hersh EV.

J Am Dent Assoc. 2001 Apr;132(4):451-6. Review.

PMID:
11315375
13.

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.

PMID:
19637402
14.
15.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
16.

Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.

Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR.

Eur Ann Allergy Clin Immunol. 2004 Jun;36(6):215-8.

PMID:
15329003
17.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
18.

Cardiovascular events and COX-2 inhibitors.

Fleming M.

JAMA. 2001 Dec 12;286(22):2808; author reply 2811-2. No abstract available.

PMID:
11735742
19.

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study.

JAMA. 2003 Jun 4;289(21):2819-26.

PMID:
12783912
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk